NEW YORK — Pfizer reported better-than-expected quarterly profits on Tuesday behind cost cuts and growth in some non-Covid-related products including the blood clot drug Eliquis.
Other pharmaceuticals with strong sales gains included Vyndaqel, used to treat nerve damage, and the products of Seagen, a cancer-focused company that Pfizer acquired in 2023.
